Lars G. Hemkens

8.3k citations

112 papers · 3.7k indexed · 3 hit papers · h-index 31

Impact in

Applied Microbiology and Biotechnology top 2%
Statistics, Probability and Uncertainty top 0.5%
- Meta-analysis and systematic reviews

Papers in

Statistics, Probability and Uncertainty 35
- Meta-analysis and systematic reviews 35
Economics and Econometrics 44
- Health Systems, Economic Evaluations, Quality of Life 42
- Pharmaceutical Economics and Policy 7

Co-authors: John P. A. Ioannidis Heiner C. Bucher H C Bucher Despina G. Contopoulos‐Ioannidis Ulrich Grouven Ralf Bender Gisbert Selke Christian Günster
Journals: Journal of Clinical Epidemiology (25 papers)Cochrane Database of Systematic Reviews (7 papers)Trials (7 papers)JAMA Network Open (6 papers)BMJ (6 papers)
Partner nations: Switzerland United States Germany

In The Last Decade

Lars G. Hemkens

102 papers receiving 3.6k citations

Hit Papers

align trajectories log scale

Searching two or more databases decreased the risk of missing relevant studies: a metaresearch study 2022 · 82 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2022 Journal of Clinical Epidemiology
2018 BMJ
2015 Environmental Health Perspectives

Peers

Countries citing papers authored by Lars G. Hemkens

Since Specialization

Citations

This map shows the geographic impact of Lars G. Hemkens's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lars G. Hemkens with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lars G. Hemkens more than expected).

Fields of papers citing papers by Lars G. Hemkens

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lars G. Hemkens. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lars G. Hemkens. The network helps show where Lars G. Hemkens may publish in the future.

Co-authors

The 25 scholars most cited alongside Lars G. Hemkens, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Lars G. Hemkens Line = papers co-authored together Lars G. Hemkens links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Core GRADE 4: rating certainty of evidence—risk of bias, publication bias, and reasons for rating up certainty BMJ ·Gordon Guyatt, Ying Wang, Prashanti Eachempati, Alfonso Iorio, M. Hassan Murad, Monica Hultcrantz, Derek K. Chu, Iván D. Flórez, Lars G. Hemkens, Thomas Agoritsas, Liang Yao, Per Olav Vandvik, Víctor M. Montori, Romina Brignardello‐Petersen	2025	9
2	Colchicine for the secondary prevention of cardiovascular events Cochrane Database of Systematic Reviews ·Fahim Ebrahimi, Ramin Ebrahimi, Marc A. Beer, Christof Schönenberger, Hannah Ewald, Matthias Briel, Perrine Janiaud, Julian Hirt, Lars G. Hemkens	2025	0
3	Personal protective effect of wearing surgical face masks in public spaces on self-reported respiratory symptoms in adults: pragmatic randomised superiority trial BMJ ·Runar Barstad Solberg, Atle Fretheim, Ingeborg Hess Elgersma, Mette Fagernes, Bjørn G Iversen, Lars G. Hemkens, Christopher James Rose, Petter Elstrøm	2024	6
4	Characteristics, consent patterns, and challenges of randomized trials using the Trials within Cohorts (TwiCs) design - A scoping review Journal of Clinical Epidemiology ·Alain Amstutz, Christof Schönenberger, Benjamin Speich, Alexandra Griessbach, Johannes M. Schwenke, Jan Glasstetter, Sophie James, Helena M. Verkooijen, Beverley Jane Nickolls, Clare Relton, Lars G. Hemkens, Frédérique Chammartin, Felix Gerber, Niklaus Daniel Labhardt, Stefan Schandelmaier, Matthias Briel	2024	2
5	Definitions of digital biomarkers: a systematic mapping of the biomedical literature BMJ Health & Care Informatics ·Ana Karen Macias Alonso, Julian Hirt, Tim Woelfle, Perrine Janiaud, Lars G. Hemkens	2024	16
6	Clinical trial evidence of quality-of-life effects of disease-modifying therapies for multiple sclerosis: a systematic analysis Journal of Neurology ·Julian Hirt, Kinga Dembowska, Tim Woelfle, Cathrine Axfors, Cristina Granziera, Jens Kühle, Ludwig Kappos, Lars G. Hemkens, Perrine Janiaud	2024	3
7	Use of pragmatic randomized trials in multiple sclerosis: A systematic overview Multiple Sclerosis Journal ·Julian Hirt, Perrine Janiaud, Pascal Düblin, G. Nicoletti, Kinga Dembowska, Thao Vy Thi Nguyen, Tim Woelfle, Cathrine Axfors, Özgür Yaldizli, Cristina Granziera, Jens Kühle, Ludwig Kappos, Lars G. Hemkens	2024	2
8	Adverse effects of opioids prescribed in opioid agonist treatment: a systematic review protocol OSF Preprints (OSF Preprints) ·Maximilian Meyer, Christian Appenzeller‐Herzog, Marco Cattaneo, Lars G. Hemkens	2023	1
9	Frequency of multiple changes to prespecified primary outcomes of clinical trials completed between 2009 and 2017 in German university medical centers: A meta-research study PLoS Medicine ·Martin Holst, Martin Haslberger, Samruddhi Yerunkar, Daniel Strech, Lars G. Hemkens, Benjamin Gregory Carlisle	2023	2
10	Using the phases of clinical development of medicines to describe clinical trials assessing other interventions is widespread but not useful Journal of Clinical Epidemiology ·Rafael Dal‐Ré, Rita Banzi, Ioana A. Cristea, César Fernández‐de‐las‐Peñas, Lars G. Hemkens, Perrine Janiaud, Marieke S. Jansen, Florian Naudet, Frits R. Rosendaal	2023	2
11	Validity of reported post-acute health outcomes in children with SARS-CoV-2 infection: a systematic review medRxiv ·Julian Hirt, Perrine Janiaud, Viktoria Gloy, Stefan Schandelmaier, Tiago Pereira, Despina G. Contopoulos‐Ioannidis, Steven N. Goodman, John P. A. Ioannidis, Klaus Munkholm, Lars G. Hemkens	2022	3
12	Central diabetes insipidus from a patient's perspective: management, psychological co-morbidities, and renaming of the condition: results from an international web-based survey The Lancet Diabetes & Endocrinology ·Cihan Atila, Paul Benjamin Loughrey, Aoife Garrahy, Bettina Winzeler, Julie Refardt, Patricia Gildroy, Malak Hamza, Aparna Pal, Joseph G. Verbalis, Christopher J. Thompson, Lars G. Hemkens, Steven Hunter, Mark Sherlock, Miles Levy, Niki Karavitaki, John Newell‐Price, John Wass, Mirjam Christ‐Crain	2022	37
13	Robustness of reported postacute health outcomes in children with SARS-CoV-2 infection: a systematic review Archives of Disease in Childhood ·Julian Hirt, Perrine Janiaud, Viktoria Gloy, Stefan Schandelmaier, Tiago Pereira, Despina G. Contopoulos‐Ioannidis, Steven N. Goodman, John P. A. Ioannidis, Klaus Munkholm, Lars G. Hemkens	2022	10
14	Reporting transparency and completeness in trials: Paper 3 – trials conducted using administrative databases do not adequately report elements related to use of databases Journal of Clinical Epidemiology ·Mahrukh Imran, Kimberly Mc Cord, Stephen J. McCall, Linda Kwakkenbos, Margaret Sampson, Ole Fröbert, Chris Gale, Lars G. Hemkens, Sinéad Langan, David Moher, Clare Relton, Merrick Zwarenstein, Edmund Juszczak, Brett D. Thombs	2021	8
15	Reporting transparency and completeness in trials: Paper 4 - reporting of randomised controlled trials conducted using routinely collected electronic records – room for improvement Journal of Clinical Epidemiology ·Stephen J. McCall, Mahrukh Imran, Lars G. Hemkens, Kimberly Mc Cord, Linda Kwakkenbos, Margaret Sampson, Sena Jawad, Merrick Zwarenstein, Clare Relton, Sinéad Langan, David Moher, Ole Fröbert, Brett D. Thombs, Chris Gale, Edmund Juszczak	2021	8
16	Reporting transparency and completeness in Trials: Paper 2 - reporting of randomised trials using registries was often inadequate and hindered the interpretation of results Journal of Clinical Epidemiology ·Kimberly A. Mc Cord, Mahrukh Imran, Danielle B. Rice, Stephen J. McCall, Linda Kwakkenbos, Margaret Sampson, Ole Fröbert, Chris Gale, Sinéad Langan, David Moher, Clare Relton, Merrick Zwarenstein, Edmund Juszczak, Brett D. Thombs, Lars G. Hemkens	2021	9
17	COVID-evidence: a living database of trials on interventions for COVID-19 OSF Preprints (OSF Preprints) ·Cathrine Axfors, Andreas M. Schmitt, (unknown), Ramon Saccilotto, Lars G. Hemkens, Perrine Janiaud, Julian Hirt	2020	9
18	Review of use of the Trials within Cohorts (TwiCs) design approach Queen Mary Research Online (Queen Mary University of London) ·Clare Relton, Beverley Jane Nickolls, Merrick Zwarenstein, Lars G. Hemkens, Rudolf Uher, Ole Fröbert, Philippa Fibert, Mahrukh Imran, Linda Kwakkenbos, Brett D. Thombs	2020	4
19	Resource use, costs, and approval times for planning and preparing a randomized clinical trial before and after the implementation of the new Swiss human research legislation PLoS ONE ·Benjamin Speich, Nadine Schur, Dmitry Gryaznov, Belinda von Niederhäusern, Lars G. Hemkens, Stefan Schandelmaier, Alain Amstutz, Benjamin Kasenda, Christiane Pauli‐Magnus, Elena Ojeda–Ruiz, Yuki Tomonaga, Kimberly A McCord, Alain Nordmann, Erik von Elm, Matthias Briel, Matthias Schwenkglenks	2019	9
20	Routinely collected data for randomized trials: promises, barriers, and implications Trials ·Kimberly A. Mc Cord, Rustam Al‐Shahi Salman, Shaun Treweek, Heidi Gardner, Daniel Strech, William Whiteley, John P. A. Ioannidis, Lars G. Hemkens	2018	89

About Lars G. Hemkens

Lars G. Hemkens is a scholar working on Statistics, Probability and Uncertainty, Economics and Econometrics, Statistics and Probability, Applied Microbiology and Biotechnology and General Health Professions, having authored 112 papers that have together received 3.7k indexed citations. Recurring topics across this work include Health Systems, Economic Evaluations, Quality of Life (42 papers), Meta-analysis and systematic reviews (35 papers), Healthcare cost, quality, practices (10 papers), Ethics in Clinical Research (9 papers), Statistical Methods in Clinical Trials (9 papers), Clinical practice guidelines implementation (9 papers), Pharmaceutical Economics and Policy (7 papers) and Health Policy Implementation Science (6 papers). The work is most often cited by research in Applied Microbiology and Biotechnology (96 citations), Statistics, Probability and Uncertainty (307 citations), Statistics and Probability (259 citations), Health, Toxicology and Mutagenesis (416 citations) and Endocrinology, Diabetes and Metabolism (489 citations). Lars G. Hemkens has collaborated with scholars based in Switzerland, United States and Germany. Frequent co-authors include John P. A. Ioannidis, Heiner C. Bucher, H C Bucher, Despina G. Contopoulos‐Ioannidis, Ulrich Grouven, Ralf Bender, Gisbert Selke, Christian Günster, P. T. Sawicki and S. Gutschmidt. Their work appears in journals such as Journal of Clinical Epidemiology, Cochrane Database of Systematic Reviews, Trials, JAMA Network Open and BMJ.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact